Clinical trial • Infectious Disease

RIFAMPICIN for Mycobacterium avium complex (MAC) pulmonary infection

Clinical trial of RIFAMPICIN for Mycobacterium avium complex (MAC) pulmonary infection.

Overview

Trial Therapeutic Area
Infectious Disease
Trial Disease
Mycobacterium avium complex (MAC) pulmonary infection
Drug Modality
Small molecule

Key dates

Initial CTIS Submission Date
04-10-2024
First CTIS Authorization Date
30-10-2024

Trial design

Randomised, comparator arm: clarithromycin (clarithromycine arrow 500 mg, modified-release tablet; maximum daily dose listed as 1000 mg). test arm: azithromycin-containing regimen (azithromycine teva 250 mg, film-coated tablet; maximum daily dose listed as 250 mg). both regimens include combination with other study antibiotics (rifadine (rifampicin) and dexambutol (ethambutol)) as part of the treatment regimens.-controlled trial across 60 sites in France.

Randomised
Yes
Comparator
Comparator arm: Clarithromycin (CLARITHROMYCINE ARROW 500 mg, modified-release tablet; maximum daily dose listed as 1000 mg). Test arm: Azithromycin-containing regimen (AZITHROMYCINE TEVA 250 mg, film-coated tablet; maximum daily dose listed as 250 mg). Both regimens include combination with other study antibiotics (RIFADINE (rifampicin) and DEXAMBUTOL (ethambutol)) as part of the treatment regimens.
Target Sample Size
424
Trial Duration For Participant
365

Eligibility

Recruits 424 Vulnerable population not selected. Participants are adults (18 years or older). Informed consent is obtained from adult participants; subject information and informed consent form documents (L1_SIS Adults, ICF Patients) are provided. No assent/parental consent procedures for children are described..

Pregnancy Exclusion
Pregnancy and breastfeeding
Vulnerable Population
Vulnerable population not selected. Participants are adults (18 years or older). Informed consent is obtained from adult participants; subject information and informed consent form documents (L1_SIS Adults, ICF Patients) are provided. No assent/parental consent procedures for children are described.

Inclusion criteria

  • {"criterion_text":"- In order to be included, each eligible patient, 18 years old or orlder, must present ATS/IDSA 2007 criteria for nontuberculous mycobacterial pulmonary infection (3). These criteria are as follows: - Clinical criteria o Respiratory symptoms and the presence of nodular or cavitary lesion on chest highresolution computed tomography. Lesions may also present in the form of diffuse micronodular syndrome.\n- AND Microbiological criteria : At least two positive cultures for MAC on two sputum specimens obtained on two different days collected at lesast 7 days apart\n- AND/OR : Positive culture for MAC on bronchoalveolar lavage or bronchoscopic aspiration\n- AND/OR : Transbronchial biopsy or surgical lung biopsy presenting histology in favour of mycobacterial infection (granuloma or positive Ziehl-Neelsen stain) and positive culture for MAC OR biopsy showing histology compatible with mycobacterial infection and one or more sputum cultures positive for MAC\n- AND : Exclusion of other diagnoses more likely than Mycobacterium avium infection on CT scan, bronchoscopy or bacteriological specimens (Bronchoscopy is not required if two good-quality sputum samples, collected 7 days apart, are available)In the presence of common bacteria, persistence of clinical symptoms and radiological signs after well-conducted antibiotic therapy suggests the diagnosis of MAC infection. The presence of criteria of Aspergillus fumigatus infection associated with the presence of microbiological criteria of MAC infection will lead to the diagnosis of MAC and Aspergillus fumigatus co-infection."}

Exclusion criteria

  • {"criterion_text":"- Known hypersensitivity to one of the molecules of the study (rifampin, ethambutol, azithromycin, clarithromycin)\n- Limited life expectancy (e.g 6 months)\n- Patients with hematologic malignancies and allogeneic haematopoietic stem cells\n- Women of childbearing age and not using an effective method of contraception (Pearl Index <1%)\n- The patient is treated with molecules prolonging the QT interval that cannot be replaced by another therapeutic class\n- The patient presents a heart failure with left ventricular ejection fraction less than 30%\n- Patient already participating in a clinical trial of a treatment or a therapeutic strategy for non-mycobacterial Tubercular\n- Relapse of MAC lung infection\n- Macrolide resistant strain, based on genotyping susceptibility testing (must be done before inclusion)\n- Treatment with molecules able to interfere with cytochrome P450 that cannot be replaced by another therapeutic class\n- HIV 1 and 2 human immunodeficiency virus infection\n- Renal failure with creatinine clearance less than 30 mL/min\n- Pregnancy and breastfeeding\n- Contraindications to one of the antibiotic\n- Inability to comply with the requirements of the protocol, especially substance abuse, according to the investigator"}

Endpoints

Primary endpoints

  • {"endpoint_text":"- The primary endpoint is the 6-month negative sputum conversion rate.","definition_or_measurement_approach":"Culture results of respiratory specimens taken 6 months after the start of treatment (6-month sputum conversion rate)."}

Secondary endpoints

  • {"endpoint_text":"- For safety: digestive toxicity (WHO criteria and Rhodes scale (28, 29)), for hepatitis (cytolysis higher than 3 times normal rate)","definition_or_measurement_approach":"Digestive toxicity assessed using WHO criteria and Rhodes scale; hepatitis defined as cytolysis greater than 3 times the normal rate."}
  • {"endpoint_text":"- Clinical improvement on analogic scales","definition_or_measurement_approach":"Clinical improvement measured using analog (visual analog) scales."}
  • {"endpoint_text":"- Radiological improvement on CT scan criteria (dimensions of the lesions compared to the baseline CT, classified as complete resolution of the lesions, partial resolution of the lesions: reduction of at least 50% of the lesions, stabilization: size of the lesion between 50% and 130% compared to baseline, deterioration of lesions: appearance of new lesions or greater than 30%","definition_or_measurement_approach":"Radiological assessment by CT scan comparing lesion dimensions to baseline and classifying as complete resolution, partial resolution (≥50% reduction), stabilization (50%–130% of baseline), or deterioration (new lesions or >30% increase)."}
  • {"endpoint_text":"- 3 and 12 months sputum conversion (Culture results of respiratory specimens taken 3 and 12 months after starting treatment)","definition_or_measurement_approach":"Culture results of respiratory specimens taken at 3 and 12 months after starting treatment."}
  • {"endpoint_text":"- 12 months outcome (death)","definition_or_measurement_approach":"All-cause mortality status at 12 months after treatment start."}
  • {"endpoint_text":"- 1 month and 6 months peak serum and mononuclear cells concentration of azithromycin and clarithromycin and their main metabolites (D-azithromycin and 14-OH clarithromycin respectively) determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS)","definition_or_measurement_approach":"Peak serum and intracellular (mononuclear cells) concentrations measured at 1 and 6 months by LC-MS/MS for azithromycin, clarithromycin and main metabolites."}
  • {"endpoint_text":"- MAC species and 6-month conversion","definition_or_measurement_approach":"6-month sputum conversion rates stratified by Mycobacterium avium complex species."}

Recruitment

Planned Sample Size
424
Recruitment Window Months
120
Consent Approach
Informed consent is obtained from each adult participant (18+). Subject information and informed consent forms are available (documents: L1_SIS Adults, ICF Patients). No procedures for assent or parental consent for minors are described.

Geography

Total Number Of Sites
60
Total Number Of Participants
424

France

Earliest CTIS Part Ii Submission Date
23-10-2024
Latest Decision Or Authorization Date
23-01-2026
Processing Time Days
457
Number Of Sites
60
Number Of Participants
424

Sites

Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumologie
Principal Investigator Name
Sophie BULIFON
Principal Investigator Email
sophie.bulifon@aphp.fr
Contact Person Name
Sophie BULIFON
Contact Person Email
sophie.bulifon@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Bactériologie
Principal Investigator Name
Christelle Guillet Caruba
Principal Investigator Email
christelle.guillet@aphp.fr
Contact Person Name
Christelle Guillet Caruba
Contact Person Email
christelle.guillet@aphp.fr
Site Name
Centre Hospitalier Universitaire De La Guadeloupe
Department Name
Pneumologie
Principal Investigator Name
Chantal Raherison Semjen
Principal Investigator Email
chantal.raherison@chu-guadeloupe.fr
Contact Person Name
Chantal Raherison Semjen
Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
Maladies respiratoires
Principal Investigator Name
Elodie BLANCHARD
Principal Investigator Email
elodie.blanchard@chu-bordeaux.fr
Contact Person Name
Elodie BLANCHARD
Site Name
Hopital Saint Joseph
Department Name
Pneumologie
Principal Investigator Name
Cristina SOCOLOVSCHI AUDOLY
Principal Investigator Email
caudoly@hopital-saint-joseph.fr
Contact Person Name
Cristina SOCOLOVSCHI AUDOLY
Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
Infectiology
Principal Investigator Name
Corine GREIB
Principal Investigator Email
carine.greib@chu-bordeaux.fr
Contact Person Name
Corine GREIB
Contact Person Email
carine.greib@chu-bordeaux.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumologie
Principal Investigator Name
Abdellatif TAZI
Principal Investigator Email
abdellatif.tazi@aphp.fr
Contact Person Name
Abdellatif TAZI
Contact Person Email
abdellatif.tazi@aphp.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumologie
Principal Investigator Name
Diane BOUVRY
Principal Investigator Email
diane.bouvry@aphp.fr
Contact Person Name
Diane BOUVRY
Contact Person Email
diane.bouvry@aphp.fr
Site Name
Centre Hospitalier Universitaire Amiens Picardie
Department Name
Pneumologie
Principal Investigator Name
Claire ANDRJEAK
Principal Investigator Email
andrejak.claire@chu-amiens.fr
Contact Person Name
Claire ANDRJEAK
Contact Person Email
andrejak.claire@chu-amiens.fr
Site Name
Centre Hospitalier Universitaire D'Angers
Department Name
Pneumologie
Principal Investigator Name
Fréderic GAGNADOUX
Principal Investigator Email
frgagnadoux@chu-angers.fr
Contact Person Name
Fréderic GAGNADOUX
Contact Person Email
frgagnadoux@chu-angers.fr
Site Name
Centre Hospitalier Le Mans
Department Name
Pneumologie
Principal Investigator Name
Marie Jouvenot
Principal Investigator Email
mjouvenot@ch-lemans.fr
Contact Person Name
Marie Jouvenot
Contact Person Email
mjouvenot@ch-lemans.fr
Site Name
Centre Hospitalier Victor Dupouy
Department Name
Pneumologie
Principal Investigator Name
Corinne APPERE-DE VECCHI
Principal Investigator Email
corinne.appere@ch-argenteuil.fr
Contact Person Name
Corinne APPERE-DE VECCHI
Site Name
Clinique De L'Europe
Department Name
Pneumologie
Principal Investigator Name
Nicolas BENOIT
Principal Investigator Email
nicohelbenoit@gmail.com
Contact Person Name
Nicolas BENOIT
Contact Person Email
nicohelbenoit@gmail.com
Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
Pneumologie
Principal Investigator Name
François Xavier BLANC
Principal Investigator Email
xavier.blanc@chu-nantes.fr
Contact Person Name
François Xavier BLANC
Contact Person Email
xavier.blanc@chu-nantes.fr
Site Name
Centre Hospitalier De Perigueux
Department Name
Pneumologie
Principal Investigator Name
Claire AGUILAR
Principal Investigator Email
claire.aguilar@ch-perigueux.fr
Contact Person Name
Claire AGUILAR
Contact Person Email
claire.aguilar@ch-perigueux.fr
Site Name
Centre Hospitalier Regional Universitaire De Tours
Department Name
Pneumologie
Principal Investigator Name
Sylvain MARCHAND-ADAM
Principal Investigator Email
sylvain.marchand-adam@univ-tours.fr
Contact Person Name
Sylvain MARCHAND-ADAM
Site Name
Centre Hospitalier Universitaire D Orleans
Department Name
Pneumologie
Principal Investigator Name
Nafissetou YOBOUET SANFO
Principal Investigator Email
nafissetou.sanfo@chr-orleans.fr
Contact Person Name
Nafissetou YOBOUET SANFO
Site Name
Centre Hospitalier Departemental Vendee
Department Name
Pneumologie
Principal Investigator Name
Marie MARCQ
Principal Investigator Email
marie.marcq@chd-vendee.fr
Contact Person Name
Marie MARCQ
Contact Person Email
marie.marcq@chd-vendee.fr
Site Name
Groupe Hospitalier Du Sud Ile De France
Department Name
Pneumologie
Principal Investigator Name
Maxence ROUYER
Principal Investigator Email
maxence.rouyer@ghsif.fr
Contact Person Name
Maxence ROUYER
Contact Person Email
maxence.rouyer@ghsif.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumologie
Principal Investigator Name
Alexandra SERRIS
Principal Investigator Email
alexandra.serris@aphp.fr
Contact Person Name
Alexandra SERRIS
Contact Person Email
alexandra.serris@aphp.fr
Site Name
Centre Hospitalier Universitaire De Nice
Department Name
Pneumologie
Principal Investigator Name
Karine RISSO
Principal Investigator Email
risso.k@chu-nice.fr
Contact Person Name
Karine RISSO
Contact Person Email
risso.k@chu-nice.fr
Site Name
Centre Hospitalier De Roubaix
Department Name
Pneumologie
Principal Investigator Name
Nicolas JUST
Principal Investigator Email
nicolas.just@ch-roubaix.fr
Contact Person Name
Nicolas JUST
Contact Person Email
nicolas.just@ch-roubaix.fr
Site Name
Centre Hospitalier D'Abbeville
Department Name
Pneumologie
Principal Investigator Name
Olivier LELEU
Principal Investigator Email
leleu.olivier@ch-abbeville.fr
Contact Person Name
Olivier LELEU
Contact Person Email
leleu.olivier@ch-abbeville.fr
Site Name
Centre Hospitalier Regional Et Universitaire De Brest
Department Name
Pneumologie
Principal Investigator Name
Cécile L'HEVEDER
Principal Investigator Email
cecile.lheveder@chu-brest.fr
Contact Person Name
Cécile L'HEVEDER
Contact Person Email
cecile.lheveder@chu-brest.fr
Site Name
Centre Hospitalier De Chauny
Department Name
Pneumologie
Principal Investigator Name
Hamza Ait Bachir
Principal Investigator Email
dr.ait-bachir@ch-chauny.fr
Contact Person Name
Hamza Ait Bachir
Contact Person Email
dr.ait-bachir@ch-chauny.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumologie
Principal Investigator Name
Bruno CRESTANI
Principal Investigator Email
bruno.crestani@aphp.fr
Contact Person Name
Bruno CRESTANI
Contact Person Email
bruno.crestani@aphp.fr
Site Name
Centre Hospitalier Universitaire De Dijon
Department Name
Pneumologie
Principal Investigator Name
Philippe BONNIAUD
Principal Investigator Email
philippe.bonniaud@chu-dijon.fr
Contact Person Name
Philippe BONNIAUD
Contact Person Email
philippe.bonniaud@chu-dijon.fr
Site Name
Hopital D'Instruction Des Armees Percy
Department Name
Pneumologie
Principal Investigator Name
Marie-alice CORNETTO
Principal Investigator Email
marie-alice.cornetto@intradef.gouv.fr
Contact Person Name
Marie-alice CORNETTO
Site Name
Les Hopitaux Universitaires De Strasbourg
Department Name
Pneumologie
Principal Investigator Name
Romain KESSLER
Principal Investigator Email
kesslerl@unistra.fr
Contact Person Name
Romain KESSLER
Contact Person Email
kesslerl@unistra.fr
Site Name
Institut Mutualiste Montsouris
Department Name
Pneumologie
Principal Investigator Name
Thibault VIEIRA
Principal Investigator Email
thibault.vieira@imm.fr
Contact Person Name
Thibault VIEIRA
Contact Person Email
thibault.vieira@imm.fr
Site Name
Centre Hospitalier Universitaire De Saint Etienne
Department Name
Pneumologie
Principal Investigator Name
Jean-Michel VERGNON
Principal Investigator Email
jean.michel.vergnon@univ-st-etienne.fr
Contact Person Name
Jean-Michel VERGNON
Site Name
Centre Hospitalier Et Universitaire De Limoges
Department Name
Pneumologie
Principal Investigator Name
Boris MELLONI
Principal Investigator Email
boris.melloni@unilim.fr
Contact Person Name
Boris MELLONI
Contact Person Email
boris.melloni@unilim.fr
Site Name
Centre Hospitalier De Versailles
Department Name
Pneumologie
Principal Investigator Name
Maria Chiara MENNITTI
Principal Investigator Email
mcmennitti@ght78sud.fr
Contact Person Name
Maria Chiara MENNITTI
Contact Person Email
mcmennitti@ght78sud.fr
Site Name
Hopital NOVO
Department Name
Pneumologie
Principal Investigator Name
Marine GOSSET-WOIMANT
Principal Investigator Email
marine.gosset-woimant@yahoo.fr
Contact Person Name
Marine GOSSET-WOIMANT
Contact Person Email
marine.gosset-woimant@yahoo.fr
Site Name
Centre Hospitalier Universitaire De Poitiers
Department Name
Pneumologie
Principal Investigator Name
Lucien GUERIN
Principal Investigator Email
Lucien.GUERIN@chu-poitiers.fr
Contact Person Name
Lucien GUERIN
Contact Person Email
Lucien.GUERIN@chu-poitiers.fr
Site Name
CHU Besancon
Department Name
Pneumologie
Principal Investigator Name
Jean-Charles DALPHIN
Principal Investigator Email
jean-charles.dalphin@univ-fcomte.fr
Contact Person Name
Jean-Charles DALPHIN
Site Name
Centre Hospitalier Regional De Marseille
Department Name
Pneumologie
Principal Investigator Name
Martine REYNAUD-GAUBERT
Principal Investigator Email
MartineLouise.REYNAUD@ap-hm.fr
Contact Person Name
Martine REYNAUD-GAUBERT
Contact Person Email
MartineLouise.REYNAUD@ap-hm.fr
Site Name
Centre Hospitalier Des Pays De Morlaix
Department Name
Pneumologie
Principal Investigator Name
David RENAULT
Principal Investigator Email
drenault@ch-morlaix.fr
Contact Person Name
David RENAULT
Contact Person Email
drenault@ch-morlaix.fr
Site Name
Centre Hospitalier Universitaire Grenoble Alpes
Department Name
Pneumologie
Principal Investigator Name
Rébecca HAMIDFAR
Principal Investigator Email
RHamidfar@chu-grenoble.fr
Contact Person Name
Rébecca HAMIDFAR
Contact Person Email
RHamidfar@chu-grenoble.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumologie
Principal Investigator Name
Jacques CADRANEL
Principal Investigator Email
jacques.cadranel@tnn.aphp.fr
Contact Person Name
Jacques CADRANEL
Contact Person Email
jacques.cadranel@tnn.aphp.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumologie
Principal Investigator Name
Pierre Régis BURGEL
Principal Investigator Email
pierre-regis.burgel@aphp.fr
Contact Person Name
Pierre Régis BURGEL
Contact Person Email
pierre-regis.burgel@aphp.fr
Site Name
Centre Hospitalier Metropole Savoie
Department Name
Pneumologie
Principal Investigator Name
Chloé HERREMAN
Principal Investigator Email
chloe.herreman@ch-metropole-savoie.fr
Contact Person Name
Chloé HERREMAN
Site Name
Centre Hospitalier Intercommunal Compiegne Noyon
Department Name
Pneumologie
Principal Investigator Name
Isabelle SIMON
Principal Investigator Email
i.simon@ch-compiegnenoyon.fr
Contact Person Name
Isabelle SIMON
Contact Person Email
i.simon@ch-compiegnenoyon.fr
Site Name
Centre Hospitalier De La Cote Basque
Department Name
Pneumologie
Principal Investigator Name
Marc-Olivier VAREIL
Principal Investigator Email
movareil@ch-cotebasque.fr
Contact Person Name
Marc-Olivier VAREIL
Contact Person Email
movareil@ch-cotebasque.fr
Site Name
Centre Hospitalier Intercommunal Creteil
Department Name
Pneumologie
Principal Investigator Name
Bernard MAITRE
Principal Investigator Email
bernard.maitre@chicreteil.fr
Contact Person Name
Bernard MAITRE
Contact Person Email
bernard.maitre@chicreteil.fr
Site Name
Centre Hospitalier Universitaire Reims
Department Name
Pneumologie
Principal Investigator Name
Gaëtan DESLEE
Principal Investigator Email
gdeslee@chu-reims.fr
Contact Person Name
Gaëtan DESLEE
Contact Person Email
gdeslee@chu-reims.fr
Site Name
Centre Hospitalier Universitaire De Caen Normandie
Department Name
Pneumologie
Principal Investigator Name
Emmanuel BERGOT
Principal Investigator Email
bergot-e@chu-caen.fr
Contact Person Name
Emmanuel BERGOT
Contact Person Email
bergot-e@chu-caen.fr
Site Name
Centre Hospitalier Universitaire De Toulouse
Department Name
Pneumologie
Principal Investigator Name
Marlène MURRIS ESPIN
Principal Investigator Email
murris.m@chu-toulouse.fr
Contact Person Name
Marlène MURRIS ESPIN
Contact Person Email
murris.m@chu-toulouse.fr
Site Name
Centre Hospitalier De Saint-Quentin
Department Name
Pneumologie
Principal Investigator Name
Hamza DOUADI
Principal Investigator Email
y.douadi@ch-stquentin.fr
Contact Person Name
Hamza DOUADI
Contact Person Email
y.douadi@ch-stquentin.fr
Site Name
Centre Hospitalier Universitaire De Montpellier
Department Name
Pneumologie
Principal Investigator Name
Arnaud BOURDIN
Principal Investigator Email
arnaud01009157@gmail.com
Contact Person Name
Arnaud BOURDIN
Contact Person Email
arnaud01009157@gmail.com
Site Name
Centre Hospitalier Simone Veil De Beauvais
Department Name
Pneumologie
Principal Investigator Name
Sabrina LENEL
Principal Investigator Email
rechercheclinique@ch-beauvais.fr
Contact Person Name
Sabrina LENEL
Site Name
Centre Hospitalier Universitaire De Rennes
Department Name
Pneumologie
Principal Investigator Name
Mallorie KERJOUAN
Principal Investigator Email
Mallorie.KERJOUAN@chu-rennes.fr
Contact Person Name
Mallorie KERJOUAN
Site Name
Centre Hospitalier Annecy Genevois
Department Name
Pneumologie
Principal Investigator Name
Gabriel MACHEDA
Principal Investigator Email
gmacheda@ch-annecygenevois.fr
Contact Person Name
Gabriel MACHEDA
Contact Person Email
gmacheda@ch-annecygenevois.fr
Site Name
Centre Hospitalier Universitaire Rouen
Department Name
Pneumologie
Principal Investigator Name
Hélène MORISSE PRADIER
Principal Investigator Email
helene.morisse@chu-rouen.fr
Contact Person Name
Hélène MORISSE PRADIER
Contact Person Email
helene.morisse@chu-rouen.fr
Site Name
Hospital Foch
Department Name
Pneumologie
Principal Investigator Name
Emilie CATHERINOT
Principal Investigator Email
e.catherinot@hopital-foch.org
Contact Person Name
Emilie CATHERINOT
Contact Person Email
e.catherinot@hopital-foch.org
Site Name
Centre Hospitalier De Cannes Simone Veil
Department Name
Pneumologie
Principal Investigator Name
Florence LE MEUNIER
Principal Investigator Email
florence.le.meunier@gmail.com
Contact Person Name
Florence LE MEUNIER
Contact Person Email
florence.le.meunier@gmail.com
Site Name
CHRU De Nancy
Department Name
Pneumologie
Principal Investigator Name
Jean-François CHABOT
Principal Investigator Email
f.chabot@chu-nancy.fr
Contact Person Name
Jean-François CHABOT
Contact Person Email
f.chabot@chu-nancy.fr
Site Name
Centre Hospitalier Universitaire De Lyon (Hospices Civils De Lyon)
Department Name
Pneumologie
Principal Investigator Name
Gilles DEVOUASSOUX
Principal Investigator Email
gilles.devouassoux@chu-lyon.fr
Contact Person Name
Gilles DEVOUASSOUX
Contact Person Email
gilles.devouassoux@chu-lyon.fr
Site Name
Assistance Publique Hopitaux De Paris
Department Name
Pneumologie
Principal Investigator Name
Nicolas VEZIRIS
Principal Investigator Email
nicolas.veziris@sorbonne-universite.fr
Contact Person Name
Nicolas VEZIRIS
Site Name
Centre Hospitalier Universitaire De Lille
Department Name
Pneumologie
Principal Investigator Name
Jean-François BERVAR
Principal Investigator Email
Jean-Francois.BERVAR@CHRU-LILLE.FR
Contact Person Name
Jean-François BERVAR

Sponsor

Primary sponsor

Full Name
Centre Hospitalier Universitaire Amiens Picardie
Organisation Type
Hospital/Clinic/Other health care facility
Country Of Registered Address
France

Investigational products

Investigational Product Name
RIFADINE 300 mg, gélule
Active Substance
RIFAMPICIN
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
Oral
Authorisation Status
34009 309 150 0 4
Maximum Dose
10 mg/kg
Investigational Product Name
CLARITHROMYCINE ARROW 500 mg, comprimé pelliculé à libération modifiée
Active Substance
CLARITHROMYCIN
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
Oral
Authorisation Status
60726518
Maximum Dose
1000 mg
Investigational Product Name
DEXAMBUTOL 500 mg, comprimé pelliculé
Active Substance
ETHAMBUTOL HYDROCHLORIDE
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
Oral
Authorisation Status
34009 311 621-7 9
Maximum Dose
20 mg/kg
Investigational Product Name
AZITHROMYCINE TEVA 250 mg, comprimé pelliculé
Active Substance
AZITHROMYCIN
Modality
Small molecule
Routes Of Administration
ORAL USE
Route
Oral
Authorisation Status
NL31563
Maximum Dose
250 mg
Combination Treatment
Yes

Related trials

Other published trials that may interest you.